Angela DeMichele
A5005537242- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cancer survivorship and care
- Estrogen and related hormone effects
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Chronic Lymphocytic Leukemia Research
- Medical Imaging Techniques and Applications
- Cancer Risks and Factors
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- PARP inhibition in cancer therapy
- MRI in cancer diagnosis
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
University of Pennsylvania
2016-2025
Abramson Cancer Center
2014-2025
Philadelphia University
2010-2025
University of Pennsylvania Health System
2009-2025
Penn Center for AIDS Research
2009-2025
ECOG-ACRIN Cancer Research Group
2025
California University of Pennsylvania
2010-2024
Translational Therapeutics (United States)
2023-2024
Sidney Kimmel Cancer Center
2015-2023
Hospital of the University of Pennsylvania
2008-2023
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed...
<h3>Importance</h3> Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. <h3>Objective</h3> To determine if pembrolizumab plus neoadjuvant (NACT) is likely to be successful 300-patient, confirmatory randomized phase 3 clinical trial. <h3>Design, Setting, and Participants</h3> The I-SPY2 study an ongoing open-label, multicenter, adaptively 2 platform trial for...
The genetic and clinical heterogeneity of breast cancer makes the identification effective therapies challenging. We designed I-SPY 2, a phase multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for cancer. goal is match responding subtypes. report results veliparib, poly(ADP-ribose) polymerase (PARP) inhibitor, combined carboplatin.In this ongoing trial, women are eligible participation if they have stage II...
MicroRNAs (miRNAs) are an abundant class of small noncoding RNAs that function as negative gene regulators. miRNA deregulation is involved in the initiation and progression human cancer; however, underlying mechanism its contributions to genome-wide transcriptional changes cancer still largely unknown. We studied epithelial ovarian by integrative genomic approach, including microarray (n = 106), array-based comparative hybridization 109), cDNA 76), tissue array 504). expression markedly...
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients who were hospitalized for COVID-19, hematologic had higher relative to solid cancer. two additional cohorts, flow cytometric serologic analyses demonstrated without similar phenotype during acute whereas impairment B cells severe respiratory syndrome 2 (SARS-CoV-2)-specific antibody responses. Despite impaired...
The heterogeneity of breast cancer makes identifying effective therapies challenging. I-SPY 2 trial, a multicenter, adaptive phase trial neoadjuvant therapy for high-risk clinical stage II or III cancer, evaluated multiple new agents added to standard chemotherapy assess the effects on rates pathological complete response (i.e., absence residual in lymph nodes at time surgery).We used randomization compare plus tyrosine kinase inhibitor neratinib with control. Eligible women were categorized...
Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter study integrating clinical, imaging, genomic data evaluate pathologic response, RFS, their relationship predictability based on biomarkers.
The combination of temsirolimus (TEM), an MTOR inhibitor, and hydroxychloroquine (HCQ), autophagy augments cell death in preclinical models. This phase 1 dose-escalation study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, pharmacodynamics HCQ with TEM cancer patients. In escalation portion, 27 patients advanced solid malignancies were enrolled, followed by a cohort expansion at top level 12 metastatic melanoma. was well tolerated, grade 3 or 4...
Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic malignancies, CAR cells ineffective for solid tumors date. We found the cell-surface molecule c-Met was expressed ∼50% breast tumors, prompting construction a cell specific c-Met, which halted tumor growth immune-incompetent mice with xenografts. then evaluated safety and feasibility treating metastatic cancer intratumoral administration...
Purpose To examine the incidence, degree, time course, treatment, and symptoms of lymphedema in breast cancer survivors. Methods We conducted a 5-year, population-based prospective study 631 randomly selected Philadelphia Delaware County, Pennsylvania female residents with incident who were diagnosed from 1999 to 2001. Using questionnaire previously validated against physical therapists’ measurement-based clinical criteria, we assigned score indicating degree (none, mild, or moderate/severe)...
A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib fulvestrant.The PALOMA-3 ( ClinicalTrials.gov identifier: NCT01942135) trial randomly assigned 521 endocrine-pretreated patients metastatic breast cancer receive plus fulvestrant or placebo fulvestrant. Primary first on 10 genes basis pathway biology and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes....
To identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 28 days (3/1 schedule) in patients with retinoblastoma protein (Rb)-positive advanced solid tumors to describe pharmacokinetic-pharmacodynamic relationships relative drug effects.This open-label phase I study (NCT00141297) enrolled who received orally six dose-escalation cohorts a standard 3 + design.Forty-one were enrolled. DLTs...
Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ combination dose-intense temozolomide (TMZ) patients advanced solid malignancies. Forty (73% metastatic melanoma) were treated oral 200 to 1200 mg daily TMZ 150 mg/m2 for 7/14 d. was well no recurrent dose-limiting toxicities...
Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant the American Clinical (ASCO) membership. ASCO considered endorsement. Methods SIO addressed management symptoms adverse effects, such as anxiety stress, mood disorders, fatigue, quality life, chemotherapy-induced nausea vomiting, lymphedema, peripheral neuropathy, pain, sleep disturbance....
Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and judge the impact of therapy recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging signatures, outcomes pathologic complete (pCR) RFS. current analysis was performed data from who had profiles did not receive trastuzumab. various classifiers tested were highly correlated. Categorization signatures...
CD25 monoclonal antibody therapy rapidly and durably depletes T regs in cancer patients through a mechanism consistent with reprogramming.
Abstract Purpose: The G1–S checkpoint of the cell cycle is frequently dysregulated in breast cancer. Palbociclib (PD0332991) an oral inhibitor CDK4/6. Based upon preclinical/phase I activity, we performed a phase II, single-arm trial palbociclib advanced Experimental Design: Eligible patients had histologically confirmed, metastatic cancer positive for retinoblastoma (Rb) protein and measureable disease. was given at 125 mg orally on days 1 to 21 28-day cycle. Primary objectives were tumor...
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk metastatic recurrence.Cell-free (cfDNA) was isolated from 291 plasma samples 84 high-risk early breast cancer patients treated in I-SPY 2 TRIAL standard NAC alone or combined MK-2206 (AKT inhibitor) treatment. Blood collected at pretreatment (T0), 3 weeks after initiation...
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
A dysbiotic microbiome can potentially contribute to the pathogenesis of many different diseases including cancer. Breast cancer is second leading cause death in women. Thus, we investigated diversity four major types breast cancer: endocrine receptor (ER) positive, triple Her2 positive and negative cancers. Using a whole genome transcriptome amplification pan-pathogen microarray (PathoChip) strategy, detected unique common viral, bacterial, fungal parasitic signatures for each types. These...